HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Chatterton, R. T Articles by Jordan, V C. Search for Related Content PubMed PubMed Citation Articles by Chatterton, R. T, Jr Articles by Jordan, V C.

¹ Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
² Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
³ The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
⁴ Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, Pennsylvania 19111, USA

(Requests for offprints should be addressed to V C Jordan at Fox Chase Cancer Center; Email: V.Craig.Jordan{at}fccc.edu)

Raloxifene is a selective oestrogen receptor modulator used clinically for the treatment and the prevention of osteoporosis in postmenopausal women. The drug has been evaluated in the Study of Tamoxifen and Raloxifene as an agent to reduce breast cancer incidence in postmenopausal women at high risk. However, about 30% of women who develop breast cancer do so in their premenopausal years. In this pilot study, salivary oestradiol and progesterone were determined throughout the menstrual cycle for a total of 22 subjects, 14 of whom completed pre- and postraloxifene (60 mg daily) salivary collections. The mean concentration of oestradiol during the menstrual cycle when subjects were taking raloxifene was significantly greater (P<0.001) than during baseline cycles. Neither salivary progesterone and cortisol nor menstrual cycle length were affected by raloxifene treatment. These data demonstrate that raloxifene administered to premenopausal women increases the concentration of oestradiol that diffuses into the salivary glands, and which presumably represents the concentration available to other organs as well. The results reflect increases in serum oestradiol reported earlier.

This article has been cited by other articles:

				J. Eng-Wong, J. Orzano-Birgani, C. K. Chow, D. Venzon, J. Yao, C. E. Galbo, J. A. Zujewski, and S. Prindiville Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1696 - 1701. [Abstract] [Full Text] [PDF]

				H. Greenlee, C. Atkinson, F. Z. Stanczyk, and J. W. Lampe A Pilot and Feasibility Study on the Effects of Naturopathic Botanical and Dietary Interventions on Sex Steroid Hormone Metabolism in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., August 1, 2007; 16(8): 1601 - 1609. [Abstract] [Full Text] [PDF]